Online citations, reference lists, and bibliographies.
← Back to Search

IDH Mutation-specific Radiomic Signature In Lower-grade Gliomas

X. Liu, Y. Li, Shaowu Li, X. Fan, Zhiyan Sun, Z. Yang, K. Wang, Z. Zhang, T. Jiang, Yong Liu, Lei Wang, Y. Wang
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Unravelling the heterogeneity is the central challenge for glioma precession oncology. In this study, we extracted quantitative image features from T2-weighted MR images and revealed that the isocitrate dehydrogenase (IDH) wild type and mutant lower grade gliomas (LGGs) differed in their expression of 146 radiomic descriptors. The logistic regression model algorithm further reduced these to 86 features. The classification model could discriminate the two types in both the training and validation sets with area under the curve values of 1.0000 and 0.9932, respectively. The transcriptome-radiomic analysis revealed that these features were associated with the immune response, biological adhesion, and several malignant behaviors, all of which are consistent with biological processes that are differentially expressed in IDH wild type and IDH mutant LGGs. Finally, a prognostic signature showed an ability to stratify IDH mutant LGGs into high and low risk groups with distinctive outcomes. By extracting a large number of radiomic features, we identified an IDH mutation-specific radiomic signature with prognostic implications. This radiomic signature may provide a way to non-invasively discriminate lower-grade gliomas as with or without the IDH mutation.
This paper references
10.1158/0008-5472.CAN-09-2650
Mutant metabolic enzymes are at the origin of gliomas.
H. Yan (2009)
10.1038/srep13087
Machine Learning methods for Quantitative Radiomic Biomarkers
Chintan Parmar (2015)
10.1002/jmri.24879
Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms
L. Grimm (2015)
10.18632/ONCOTARGET.588
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Y. Jiao (2012)
10.1126/scitranslmed.3002693
Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
O. Andronesi (2012)
10.1111/ene.12578
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel‐based radiographic study of 146 low‐grade gliomas
Y. Wang (2015)
10.1038/nprot.2008.211
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
D. Huang (2008)
10.1371/journal.pone.0091216
Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma
X. Guan (2014)
10.1111/ene.12578
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel‐based radiographic study of 146 low‐grade gliomas
Y. Wang (2015)
10.1093/neuonc/now061
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
X. Zhang (2016)
Huse www.aging-us.com JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lowergrade glioma
K Kannan (2012)
10.1007/s00401-007-0243-4
The 2007 WHO Classification of Tumours of the Central Nervous System
D. N. Louis (2007)
10.1371/journal.pone.0091216
Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma
X. Guan (2014)
10.1126/science.1170944
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
S. Zhao (2009)
10.1102/1470-7330.2010.0021
Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage
B. Ganeshan (2010)
10.1038/srep16238
IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
P. Kickingereder (2015)
10.1016/j.canlet.2016.01.024
CGCG clinical practice guidelines for the management of adult diffuse gliomas.
T. Jiang (2016)
10.1016/j.crad.2011.08.012
Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival.
B. Ganeshan (2012)
10.1002/jmri.24879
Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms
L. Grimm (2015)
10.1038/NCOMMS5644
Corrigendum: Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
H. Aerts (2014)
Localizing seizuresusceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping. Neuro-oncology
Y Wang (2015)
10.18632/ONCOTARGET.588
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Y. Jiao (2012)
10.1038/nprot.2008.211
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
D. Huang (2008)
10.1093/neuonc/now061
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
X. Zhang (2016)
10.1016/j.radonc.2015.02.015
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma.
T. Coroller (2015)
10.1126/scitranslmed.aaa7582
Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities
Haruka Itakura (2015)
IDH1 and IDH2 mutations in gliomas.
F. Ducray (2009)
10.1158/0008-5472.CAN-09-2650
Mutant metabolic enzymes are at the origin of gliomas.
H. Yan (2009)
10.1158/0008-5472.CAN-15-0934
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
U. Emir (2016)
10.1016/J.YNEU.2012.05.008
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
J. Uhm (2012)
Huse www.aging-us.com 684 AGING JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lowergrade glioma
K Kannan (2012)
10.18632/ONCOTARGET.2585
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis
X. Liu (2014)
10.1038/srep13087
Machine Learning methods for Quantitative Radiomic Biomarkers
Chintan Parmar (2015)
Huse www.aging-us.com 684 AGING JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lowergrade glioma
K Kannan (2012)
Cancerassociated IDH1 mutations produce 2hydroxyglutarate
L Dang (2009)
10.1111/j.1750-3639.2009.00352.x
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
D. Capper (2010)
IDH1 and IDH2 mutations in gliomas.
F. Ducray (2009)
10.1227/NEU.0000000000000812
Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas.
Stephen J. Price (2015)
Localizing seizuresusceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping. Neuro-oncology
Y Wang (2015)
10.1093/neuonc/nov239
Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Kai Wang (2016)
10.1111/j.1750-3639.2009.00352.x
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
D. Capper (2010)
10.1148/radiol.201171051
Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma.
J. Pérez-Beteta (2018)
10.1038/ncomms5006
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
H. Aerts (2014)
10.18632/ONCOTARGET.2585
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis
X. Liu (2014)
10.1016/j.ejca.2011.11.036
Radiomics: extracting more information from medical images using advanced feature analysis.
P. Lambin (2012)
10.1227/NEU.0000000000000812
Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas.
Stephen J. Price (2015)
10.1016/j.canlet.2016.01.024
CGCG clinical practice guidelines for the management of adult diffuse gliomas.
T. Jiang (2016)
10.1007/s00432-013-1519-9
Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China
C. Zhang (2013)
Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acqui www.aging-us.com 686 AGING sition protocol and tissue site exert substantial influence
L Dercle (2017)
10.2353/jmoldx.2010.090237
A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples.
Prashanth Setty (2010)
Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. Oncotarget
CB Zhang (2015)
Isocitrate dehydrogenase mutations in gliomas. Neurooncology
MS Waitkus (2016)
10.1093/neuonc/nos263
Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.
W. Yan (2012)
Isocitrate dehydrogenase mutations in gliomas. Neurooncology
MS Waitkus (2016)
10.1126/scitranslmed.aaa7582
Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities
Haruka Itakura (2015)
10.1038/srep11044
Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer
Chintan Parmar (2015)
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas. Cancer letters
H Hu (2015)
10.1200/JCO.2009.21.9832
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
M. Sanson (2009)
10.1097/NEN.0b013e3181c391be
Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues
C. Horbinski (2009)
10.1126/science.1170944
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
S. Zhao (2009)
Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acqui www.aging-us.com 686 AGING sition protocol and tissue site exert substantial influence
L Dercle (2017)
10.1093/neuonc/nou130
Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping.
Y. Wang (2015)
10.1097/NEN.0b013e3181c391be
Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues
C. Horbinski (2009)
10.2353/jmoldx.2010.090237
A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples.
Prashanth Setty (2010)
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
C Choi (2012)
10.1007/s11060-014-1614-z
Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging
Seunghyun Lee (2014)
10.1200/JCO.2009.21.9832
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
M. Sanson (2009)
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
C Choi (2012)
10.1038/srep16238
IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
P. Kickingereder (2015)
10.1007/s11060-014-1614-z
Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging
Seunghyun Lee (2014)
10.1038/s41598-017-08310-5
Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence
L. Dercle (2017)
10.1016/j.canlet.2014.12.018
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
H. Hu (2015)
Cancerassociated IDH1 mutations produce 2hydroxyglutarate
L Dang (2009)
10.1126/scitranslmed.3002693
Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
O. Andronesi (2012)
10.1016/j.canlet.2014.12.018
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
H. Hu (2015)
10.1111/jcmm.13863
A four‐gene‐based prognostic model predicts overall survival in patients with hepatocellular carcinoma
Junyu Long (2018)
Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. Oncotarget
CB Zhang (2015)
10.1111/jcmm.13863
A four‐gene‐based prognostic model predicts overall survival in patients with hepatocellular carcinoma
Junyu Long (2018)
10.3174/ajnr.A3803
Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astrogliomas? A Retrospective Study of 112 Cases
W. L. Tan (2014)
10.1093/neuonc/nov136
Isocitrate dehydrogenase mutations in gliomas.
Matthew S. Waitkus (2016)
10.1016/j.ejca.2011.11.036
Radiomics: extracting more information from medical images using advanced feature analysis.
P. Lambin (2012)
10.1093/neuonc/not159
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Jason Beiko (2014)
10.3174/ajnr.A3803
Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astrogliomas? A Retrospective Study of 112 Cases
W. L. Tan (2014)
10.1016/j.crad.2011.08.012
Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival.
B. Ganeshan (2012)
10.1007/s00401-016-1545-1
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
D. N. Louis (2016)
10.1007/s00401-014-1370-3
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
D. Reuss (2014)
10.1038/srep11044
Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer
Chintan Parmar (2015)
10.1148/radiol.201171051
Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma.
J. Pérez-Beteta (2018)
10.1007/s00401-014-1370-3
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
D. Reuss (2014)
10.1102/1470-7330.2010.0021
Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage
B. Ganeshan (2010)
10.1007/s00401-016-1545-1
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
D. N. Louis (2016)
10.1007/s00432-013-1519-9
Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China
C. Zhang (2013)
10.1093/neuonc/not159
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
Jason Beiko (2014)
10.3109/0284186X.2013.812798
Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability
R. Leijenaar (2013)
10.1016/J.YNEU.2012.05.008
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
J. Uhm (2012)
10.1158/0008-5472.CAN-15-0934
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.
U. Emir (2016)
10.1016/j.radonc.2015.02.015
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma.
T. Coroller (2015)
10.3109/0284186X.2013.812798
Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability
R. Leijenaar (2013)
10.18632/oncotarget.5421
Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling
C. Zhang (2015)
10.1093/neuonc/nov239
Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Kai Wang (2016)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar